Trial Profile
A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination With Pazopanib for Refractory Soft Tissue Sarcoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Gemcitabine
- Indications Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 31 May 2020 Status changed to discontinued.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 01 Aug 2019 Planned End Date changed from 1 Mar 2019 to 30 Jun 2020.